Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Specimen Handling 51pembrolizumab 46Magnetic Resonance Spectroscopy 38Biopsy 37Cyclophosphamide 34fludarabine 29Cetuximab 20Cisplatin 19Carboplatin 19Radiotherapy 16Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Nivolumab 14Fluorouracil 14fludarabine phosphate 13Leucovorin 13Gemcitabine 13Temozolomide 11Pemetrexed 11Oxaliplatin 11Cytarabine 11Paclitaxel 10Irinotecan 10Ipilimumab 10130-nm albumin-bound paclitaxel 10Prednisone 9Immunoglobulin G 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Colony-Stimulating Factors × 30 days × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡